scholarly journals A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM/2010-04 study

Oncotarget ◽  
2017 ◽  
Vol 8 (42) ◽  
pp. 73144-73153 ◽  
Author(s):  
Alberto Ocana ◽  
Marta Gil-Martin ◽  
Miguel Martín ◽  
Federico Rojo ◽  
Silvia Antolín ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Phase I ◽  
Advanced Breast Cancer ◽  
Phase I Study ◽  
Kinase Inhibitor ◽  
Src Kinase ◽  
Advanced Breast ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy

High Efficacy of Paclitaxel and Doxorubicin as First-Line Therapy in Advanced Breast Cancer: A Phase I-II Study

2000 ◽  
Vol 12 (4) ◽  
pp. 367-373 ◽  
Author(s):  
M. De Lena ◽  
A. Latorre ◽  
P. Calabrese ◽  
A. Catino ◽  
V. Lorusso ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Phase I ◽  
Advanced Breast Cancer ◽  
Advanced Breast ◽  
High Efficacy ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy

Anastrozole Versus Tamoxifen as First-Line Therapy in Postmenopausal Patients With Hormone-Dependent Advanced Breast Cancer

2003 ◽  
Vol 26 (3) ◽  
pp. 317-322 ◽  
Author(s):  
Alfredo Milla-Santos ◽  
Lidon Milla ◽  
Jordi Portella ◽  
Lidon Rallo ◽  
Maria Pons ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Advanced Breast ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy

scholarly journals Phase I study of QLNC120, a novel EGFR and HER2 kinase inhibitor, in pre-treated patients with HER2-overexpressing advanced breast cancer

Oncotarget ◽  
2016 ◽  
Vol 8 (22) ◽  
pp. 36750-36760 ◽  
Author(s):  
Tongtong Zhang ◽  
Qing Li ◽  
Shanshan Chen ◽  
Yang Luo ◽  
Ying Fan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Phase I ◽  
Advanced Breast Cancer ◽  
Phase I Study ◽  
Kinase Inhibitor ◽  
Advanced Breast

Phase III Study of Letrozole Versus Tamoxifen as First-Line Therapy of Advanced Breast Cancer in Postmenopausal Women: Analysis of Survival and Update of Efficacy From the International Letrozole Breast Cancer Group

2003 ◽  
Vol 21 (11) ◽  
pp. 2101-2109 ◽  
Author(s):  
Henning Mouridsen ◽  
Mikhail Gershanovich ◽  
Yan Sun ◽  
Ramón Pérez-Carrión ◽  
Corrado Boni ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Postmenopausal Women ◽  
Endocrine Therapy ◽  
Advanced Breast ◽  
Phase Iii ◽  
Karnofsky Performance Score ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy

Purpose: To analyze overall survival (OS) and update efficacy data for letrozole versus tamoxifen as first-line therapy in postmenopausal women with locally advanced or metastatic breast cancer. Patients and Methods: This multicenter phase III trial randomly assigned 916 patients with hormone receptor–positive or unknown tumors letrozole 2.5 mg (n = 458) or tamoxifen 20 mg (n = 458) daily until disease progression. Optional cross-over was permitted at the treating physician’s discretion. This report updates efficacy at a median follow-up of 32 months. Results: The superiority of letrozole to tamoxifen was confirmed for time to progression (median, 9.4 v 6.0 months, respectively; P < .0001), time to treatment failure (median, 9 v 5.7 months, respectively; P < .0001), overall objective response rate (32% v 21%, respectively; P = .0002), and overall clinical benefit. Median OS was slightly prolonged for the randomized letrozole arm (34 v 30 months, respectively). Although this difference in OS is not significant, survival was improved in the randomized letrozole arm over the first 2 years of the study. Approximately one half of the patients in each arm crossed over. Total duration of endocrine therapy (“time to chemotherapy”) was significantly longer (P = .005) for patients initially on letrozole (median, 16 months) than for patients initially on tamoxifen (median, 9 months). Time to worsening of Karnofsky performance score was significantly delayed with letrozole compared with tamoxifen (P = .001). Conclusion: This study documents the superiority of letrozole over tamoxifen in first-line endocrine therapy in postmenopausal women with advanced breast cancer.

Sign in / Sign up

Export Citation Format

Share Document